NR4A1 and invasive breast carcinoma: The Food and Drug Administration has approved tamoxifen for treating hormone receptor-positive, invasive, and non-invasive breast cancer post-completion of primary therapy with surgery and/or radiation to reduce the risk of recurrence and improve survival rates [4].